Holobiome, a Boston, MA-based biotechnology company generating products that can improve health through multiple marketplaces, raised an undisclosed amount in Seed funding.
The round was led by iSelect Fund, with participation from Corundum Systems Biology, Satori Neuro, SkyRiver Ventures, Pace Ventures, Valor Equity Partners, and Astanor. As part of the funding round, Dr. Joan LaRovere, Operating Partner of iSelect and Associate Chief Medical Officer for Transformation at Boston Children’s Hospital, will join Dr. Iain Chessell, Global Head of Neuroscience of AstraZeneca, and Dr. Strandwitz on Holobiome’s board of directors.
The company intends to use the funds to advance its lead program in depression into human testing, expand its platform, and build out expansive analytical pipelines coupled with real-world datasets.
Led by CEO Dr. Philip Strandwitz, Holobiome is a biotechnology company that leverages the potential of the human gut microbiome to generate products that can improve health through multiple marketplaces. Its platform is empowered by its Microbiome Vault and proprietary tools to understand which functions gut bacteria perform that may impact health. Its initial focus is on targeting the gut-brain-axis, and its lead asset is a probiotic targeting biology relevant for depression. Through a partnership model, the company is advancing programs with consumer, food, and pharmaceutical partners in other areas, like stress and pain.
FinSMEs
09/10/2024